ArticleThe journal of allergy and clinical immunology. Global2026
The use of triple therapy, ICS/LABA/LAMA, in the treatment of asthma: A real-life Latin-American specialized centers experience.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Formulation and Technological Strategies for Montelukast Pulmonary Delivery.ACS omega · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The use of triple therapy with inhaled corticosteroids (ICSs), long-acting beta-agonists (LABAs), and long-acting muscarinic antagonists (LAMAs) is increasingly common in asthma management, particularly in patients with uncontrolled disease. However, real-world data from Latin-American settings are limited. Objective: We sought to compare asthma control and exacerbation frequency among patients receiving ICS/LABA/LAMA versus ICS/LABA alone at steps 4 and 5 of the Global Initiative for Asthma guidelines in specialized centers in Mexico. Methods: A cross-sectional observational study was conducted in 3 allergy and pulmonary clinics. Adult patients with asthma receiving maintenance therapy at Global Initiative for Asthma step 4 or 5 were recruited. Demographic, clinical, and spirometric data were collected. Asthma control was assessed using the asthma control test. Comparisons were made between patients receiving ICS/LABA/LAMA and those receiving ICS/LABA only. Ordinal logistic regression was used to identify predictors of asthma control. Results: Among 279 patients (71% female; mean age, 51.4 ± 12.3 years), 79 received triple therapy. At step 4, ICS/LABA/LAMA users had better asthma control than those on ICS/LABA alone ( Conclusions: ICS/LABA/LAMA may improve asthma control at step 4 but not at step 5, possibly due to more severe disease and previous use of biologics in the latter group. These findings highlight the need for tailored therapy and better phenotyping in severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.